Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators

In the last two years, clinical trials with blocking antibodies to the negative checkpoint regulators CTLA-4 and PD-1 have rekindled the hope for cancer immunotherapy. Multiple negative checkpoint regulators protect the host against autoimmune reactions but also restrict the ability of T cells to ef...

Celý popis

Podrobná bibliografia

Vydané v:	Frontiers in immunology Ročník 6; s. 418
Hlavní autori:	Le Mercier, Isabelle, Lines, J. Louise, Noelle, Randolph J.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland Frontiers Media S.A 21.08.2015
Predmet:	Autoimmunity BTLA cancer immunotherapy Immunology LAG-3 TIGIT TIM-3 VISTA autoimmunity LAG-3 cancer immunotherapy BTLA negative checkpoint regulators TIGIT TIM-3
ISSN:	1664-3224, 1664-3224
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!